Background Metformin is an oral anti‐hyperglycemic agent that has been shown to reduce
total mortality compared to other anti‐hyperglycemic agents, in the treatment of type 2 …

Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …

Аннотация Современная диабетология обращает самое серьезное внимание на
метаболизм жировой ткани потому, что жировая ткань очень тесно связана с …

Aims/hypothesis The aim of this work was to compare the glucose-lowering efficacy of
dipeptidyl peptidase-4 (DPP-4) inhibitors between Asian and non-Asian patients with type 2 …

Background: Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in
patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We …

Aim: To evaluate the efficacy and safety of the potent and selective dipeptidyl peptidase‐4
(DPP‐4) inhibitor linagliptin administered as add‐on therapy to metformin in patients with …

BACKGROUND: Considerable clinical data on the treatment of type 2 diabetes with incretin-
based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl …

Abstract The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent
insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of …

Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for the management of type 2
diabetes. Direct comparisons with active glucose-lowering comparators in drug-naive …

Aim: To show that vildagliptin added to metformin is non‐inferior to glimepiride in reducing
HbA1c levels from baseline over 2 years. Methods: A randomized, double‐blind, active …